Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New anti-psychotic drugs no better than older, cheaper ones

05.12.2006
A study led by The University of Manchester’s Division of Psychiatry has found that schizophrenia patients respond just as well - and perhaps even better - to older psychiatric drugs as newer, costlier alternatives.

According to the study, funded by the NHS and published in the Archives of General Psychiatry, patients with schizophrenia whose medication is being changed gain little benefit from being put on the newer drugs - despite their much larger market share. This runs contrary to the widely-held view that second-generation anti-psychotics are safer and more effective than the less expensive first-generation.

Antipsychotic medication is the main method of treating schizophrenia, with most UK patients currently receiving second-generation drugs through the NHS which cost at least 10 times more than their predecessors. Previous, industry-sponsored trials reported these newer drugs to be more effective and better tolerated, leading most experts to currently recommend using them first despite their additional cost.

Study leader Professor Shôn Lewis said: “The development of second-generation anti-psychotics was thought to be a major advance, as the first trials seemed to show they reduced side effects. Claims that they were also more effective than first-generation drugs shifted treatment patterns away from these medications, even though previous research comparing the drug classes has had mixed results.”

The NHS commissioned the study – the first ever to compare treatment results in this area – to assess whether the additional costs of second-generation anti-psychotics were off-set by improvements in patients’ quality of life or reductions in the use of health and social care services.

“We undertook the study thinking that we would show the NHS that their misgivings about the previous data were unfounded,” Professor Lewis said.

The team, which includes colleagues at the University of Cambridge, Institute of Psychiatry and Imperial College London, studied 227 schizophrenia patients for whom a change in drug treatment was being considered (because of ineffectiveness or harmful side effects). The participants were randomly assigned to receive one class of drug or the other, with doctors determining which of the first- or second-generation medications would be best for each patient.

They were assessed before and 12, 26 and 52 weeks after the change in treatment using a quality of life scale, and symptoms, side effects, treatment costs and satisfaction with the drug were also measured.

The results failed to reveal the advantage in side effects or effectiveness predicted for the second generation drugs; instead there was a trend towards the older drugs working better.

Professor Lewis said: “We estimated that the second-generation anti-psychotics would produce a five-point improvement in quality of life scores, compared with first-generation anti-psychotics. But after 12 weeks, the quality of life scores averaged 49.2 for the first-generation group and 46.6 for the second-generation group.”

After 26 weeks, the first-generation group score averaged 49.2, compared with and 50.4 for second-generation, but after a year it was 53.2 for first-generation users and 51.3 for second-generation. Participants in the first-generation group also showed a trend toward greater improvements in symptoms.

“We were so certain we would find exactly the opposite that we went back and checked the data,” Professor Lewis continued. “But it all suggested that careful prescribing of first-generation anti-psychotics, at least in the context of a trial, is not associated with poorer efficacy or a greater adverse effect.

A parallel trial, also funded by the NHS, did confirm previous reports that the second generation drug clozapine stood out from the others in terms of effectiveness for people with severe schizophrenia. “This drug improved quality of life and symptoms better than the other newer drugs, and patients preferred it,” Professor Lewis said.

“However, our research suggests that, despite modern prescribing patterns, second-generation anti-psychotics are not the great breakthrough they were once thought to be – and certainly may not justify their ten-times higher price tag. Further trials to evaluate both the role of second-generation anti-psychotics in the management of schizophrenia and the usefulness of cheaper, older drugs could save the NHS millions of pounds.”

Jon Keighren | alfa
Further information:
http://www.manchester.ac.uk/aboutus/news/

More articles from Health and Medicine:

nachricht 'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers
16.02.2018 | National University of Science and Technology MISIS

nachricht New process allows tailor-made malaria research
16.02.2018 | Eberhard Karls Universität Tübingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Contacting the molecular world through graphene nanoribbons

19.02.2018 | Materials Sciences

When Proteins Shake Hands

19.02.2018 | Materials Sciences

Cells communicate in a dynamic code

19.02.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>